4
Clinical Trials associated with Anti-CD19 CAR T-cell therapy (Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences )Exploratory Clinical Study to Evaluate the Safety and Efficacy of Autologous CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
Autoimmune diseases such as systemic lupus erythematosus (SLE), diffuse cutaneous systemic sclerosis (dcSSc), antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV), idiopathic inflammatory myopathy (IIM), and Sjogren's syndrome (SS) have complex etiologies and are prone to cause systemic multiple organ damage. Because patients need lifelong medication due to repeated disease recurrence, and the current treatment of the above autoimmune diseases has limited efficacy and greater side effects, so that patients bear an excessive burden of disease, therefore, there is an urgent need to explore safer and more effective treatment.
Several autologous CAR-T products targeting CD19 have been marketed for the treatment of B-cell hematological malignancies. Depletion of B cells to suppress abnormal immune responses is also currently one of the popular strategies for the treatment of antibody-mediated autoimmune diseases, and many clinical studies of CAR-T against autoimmune diseases are still ongoing.
Therefore, a dose escalation trial is planned to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T in patients with relapsed/refractory autoimmune diseases.
Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.
100 Clinical Results associated with Anti-CD19 CAR T-cell therapy (Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences )
100 Translational Medicine associated with Anti-CD19 CAR T-cell therapy (Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences )
100 Patents (Medical) associated with Anti-CD19 CAR T-cell therapy (Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences )
100 Deals associated with Anti-CD19 CAR T-cell therapy (Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences )